Senores Pharmaceuticals’ board re-appoints its Managing Director and a Whole Time Director for three years

Senores Pharmaceuticals Limited has told the exchanges that its board, at a meeting on 13 Oct 2026, approved the re-appointment of Mr. Swapnil Jatinbhai Shah as Managing Director for three consecutive years from 15 Oct 2026, and of Mr. Chetan Bipinchandra Shah as Whole Time Director for three consecutive years from 10 Nov 2026. Both are liable to retire by rotation, and both are subject to shareholder approval through a postal ballot.

The board acted on the recommendation of its Nomination and Remuneration Committee. The filing describes Mr. Swapnil Shah as the promoter and Managing Director, with over 15 years of experience in the pharmaceutical sector. He holds an MBA from Hofstra University, New York and a degree in chemical engineering from Nirma University, and leads the company's overall functioning, product portfolio, strategy and business development.

Mr. Chetan Shah is the Whole Time Director and Chief Operating Officer, with over 30 years of experience, of which 25 are in the pharmaceutical industry. He has previously been associated with Torrent Pharmaceuticals and Cadila Pharmaceuticals, among others, and is responsible for capacity expansion, capital expenditure planning, supply chain and manufacturing. The filing says the two are not related to each other or to any other director, and neither is debarred from holding office as a director.

Inference

The filing records continuity in the top management team: the Managing Director and the Chief Operating Officer would continue in their roles for three more years. This is a leadership decision, and the filing gives no figures or changes in strategy.

The re-appointments are not final until shareholders approve them through the postal ballot. Shareholders may want to look out for the postal ballot notice and the terms of remuneration it sets out, which are not part of this filing.